



US009814751B2

(12) **United States Patent**
Mosher et al.

(10) **Patent No.:** **US 9,814,751 B2**
(45) **Date of Patent:** ***Nov. 14, 2017**

(54) **LISINOPRIL FORMULATIONS**

(71) Applicant: **Silvergate Pharmaceuticals, Inc.,**
Greenwood Village, CO (US)

(72) Inventors: **Gerold L. Mosher**, Kansas City, MO
(US); **David W. Miles**, Kansas City,
MO (US)

(73) Assignee: **SILVERGATE**
PHARMACEUTICALS, INC.,
Greenwood Village, CO (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **15/483,691**

(22) Filed: **Apr. 10, 2017**

(65) **Prior Publication Data**

US 2017/0209523 A1 Jul. 27, 2017

Related U.S. Application Data

(63) Continuation of application No. 15/268,095, filed on
Sep. 16, 2016, now Pat. No. 9,616,096, which is a
continuation of application No. 14/934,752, filed on
Nov. 6, 2015, now Pat. No. 9,463,183.

(60) Provisional application No. 62/249,011, filed on Oct.
30, 2015.

(51) **Int. Cl.**

A61K 38/05 (2006.01)

A61K 47/12 (2006.01)

A61K 9/00 (2006.01)

A61K 47/26 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 38/05** (2013.01); **A61K 9/0053**
(2013.01); **A61K 47/12** (2013.01); **A61K 47/26**
(2013.01)

(58) **Field of Classification Search**

CPC **A61K 9/0053**; **A61K 38/05**; **A61K 47/12**;
A61K 47/26

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,374,829 A 2/1983 Harris et al.
4,472,380 A 9/1984 Harris et al.
4,510,083 A 4/1985 Blacklock et al.
4,743,450 A 5/1988 Harris et al.
4,793,998 A 12/1988 Murthy et al.
4,830,853 A 5/1989 Murthy et al.
4,931,430 A 6/1990 Sudilovsky et al.
5,049,553 A 9/1991 Sudilovsky
5,698,562 A 12/1997 Mendes et al.
6,028,222 A 2/2000 Dietlin et al.
6,300,361 B1 10/2001 Vivilecchia et al.
6,300,362 B1 10/2001 Vivilecchia et al.

6,413,988 B1 7/2002 De Proost
6,509,350 B2 1/2003 Vivilecchia et al.
6,790,861 B2 9/2004 Vivilecchia et al.
6,869,963 B2 3/2005 Patel et al.
6,977,257 B2 12/2005 Parab et al.
7,101,888 B2 9/2006 Reo et al.
7,605,148 B2 10/2009 Batta et al.
8,153,824 B2 4/2012 Sesha
8,568,747 B1 10/2013 Rajewski et al.
8,778,366 B2 7/2014 Rajewski et al.
8,927,028 B2 1/2015 Grenier et al.
9,463,183 B1* 10/2016 Mosher A61K 47/12
9,616,096 B1* 4/2017 Mosher A61K 47/12
2004/0171669 A1 9/2004 Chenevier
2004/0258757 A1 12/2004 Bosch et al.
2006/0094760 A1 5/2006 Fawzy et al.
2007/0265344 A1 11/2007 Strobel et al.
2008/0221156 A1* 9/2008 Spireas A61K 9/1694
514/307
2008/0234291 A1 9/2008 Francois et al.
2009/0206287 A1 8/2009 Trupke et al.
2009/0269287 A1* 10/2009 Berta A61Q 11/00
424/52
2010/0222334 A1* 9/2010 Talamonti A61K 9/0095
514/224.2
2011/0003798 A1* 1/2011 Okram C07D 471/04
514/224.2
2014/0100260 A1 4/2014 Rajewski et al.
2015/0148335 A1 5/2015 Bova et al.
2015/0258027 A1 9/2015 Rajewski et al.
2017/0119840 A1 5/2017 Mosher et al.
2017/0209523 A1 7/2017 Mosher et al.

FOREIGN PATENT DOCUMENTS

CA 1275350 C 10/1990
EP 2903690 A1 8/2015
WO WO-9814196 A1 4/1998
WO WO-0145667 A2 6/2001

(Continued)

OTHER PUBLICATIONS

Lisinopril "Lisinopril 1mg/ml Oral Liquid" retrieved from www.
uspharmacist.com.*

Ahlin et al., "Investigation of polymeric nanoparticles as carriers of
enalaprilat for oral administration," Int'l Journ. Pharmaceutics, 239,
pp. 113-120 (2002).

Allen et al., "Stability of alprazolam, chloroquine phosphate,
cisapride, enalapril maleate, and hydralazine hydrochloride in
extemporaneously compounded oral liquids," Am J. Health-Syst
Pharm, vol. 55, pp. 1915-1920, (1998).

Allen, Lisinopril 1 mg/mL oral liquid US Pharm., 38(2):36-37
(2013).

Al-Omari et al. "Effect of the drug-matrix on the stability of
enalapril maleate in tablet formulations" Journal of Pharmaceutical
and Biomedical Analysis, vol. 25:893-902 (2001).

(Continued)

Primary Examiner — Sean M Basquill

(74) *Attorney, Agent, or Firm* — Wilson Sonsini Goodrich
& Rosati

(57)

ABSTRACT

Provided herein are stable lisinopril oral liquid formulations.
Also provided herein are methods of using lisinopril oral
liquid formulations for the treatment of certain diseases
including hypertension, heart failure and acute myocardial
infarction.

20 Claims, 2 Drawing Sheets